PD Dr. Dr. med. Friedemann Honecker
Specialist in cancer and blood disorders
Treatment of tumor and blood disorders; FMH General Internal Medicine and Hematology; Hematology and Oncology (D)
Additional qualification in palliative medicine (D)
Highly specialized in the medical-oncological treatment of urogenital tumors (bladder, testicular, kidney and prostate cancer)
Career path
06/2022
Partner of TumorZentrum Ostschweiz AG
12/2015
Partner of Tumor- und Brustzentrum ZeTuP AG
02/2013
Established internist specializing in hematology and internal oncology, Tumor- und Brustzentrum ZeTuP AG, St. Gallen
09-12/2012
Senior Physician, Central Emergency Department of the University Hospital Hamburg-Eppendorf (interdisciplinary care of medical emergencies)
02/2012
Managing Senior Physician of the Department of Oncology, Hematology and Bone Marrow Transplantation with the Pneumology Section, University Hospital Hamburg-Eppendorf
05/2011
Head of “Uro-Oncology” of the Department of Oncology, Hematology and Bone Marrow Transplantation with the Pneumology Section, University Hospital Hamburg-Eppendorf
12/2010
Acquisition of the additional qualification in “Palliative Medicine”
08/2009
Senior Physician, Department of Oncology, Hematology and Bone Marrow Transplantation with the Pneumology Section, University Hospital Hamburg-Eppendorf
01/2009
Specialist in Internal Medicine with a focus on Hematology and Oncology (D)
11/2007
Specialist in Internal Medicine (D)
06/2007
Member of the “Palliative Care Team” of the University Hospital Hamburg-Eppendorf
Show more
01/2005 – 07/2009 04-12/2004 02/2002 – 03/2004 01/2002 07/1999 – 12/2001 1998 – 1999 1995 – 1999 1994 – 1995 1991 – 1994
Resident Physician, Department of Oncology, Hematology and Bone Marrow Transplantation with the Pneumology Section, University Hospital Hamburg-Eppendorf
Resident Physician, Department of Hematology, Oncology, Immunology and Rheumatology, University Hospital Tübingen
Research stay at Erasmus Medical Center, Rotterdam, with a grant from the German Cancer Aid, research focus: development of normal and malignant human germ cells
Assistant Physician, Department of Hematology, Oncology, Immunology and Rheumatology, University Hospital of Tübingen
Physician in internship, Department of Hematology, Oncology, Immunology and Rheumatology, University Hospital of Tübingen
Practical Year: Auckland, New Zealand; University Hospital Benjamin Franklin, Berlin; McGill University, Montreal, Canada
Studied Human Medicine at the Free University of Berlin
Year abroad at Newcastle Medical School, Newcastle-upon-Tyne, England
Studied Human Medicine at the Medical University of Lübeck
Further activities
03/2022 – 10/2023
Member of the “Core Group” of the national research group «Breast Cancer» of the Swiss Group for Clinical Cancer Research (SAKK)
Since 01/2018
Elected member of the Ethics Committee of Eastern Switzerland (EKOS)
11/2010
Habilitation in Internal Medicine with the title “Comparative characterization of normal and malignant human germ cells”, Medical Faculty of the University of Hamburg
Since 2002
Experimental and clinical research on urogenital tumors, especially germ cell tumors (clinical and experimental) and prostate carcinomas (clinical) focusing on chemotherapy resistance, testing new cytostatic substances, developing new treatment strategies, and conducting clinical trials. 2005 – 2013 Head of the Laboratory for Experimental Oncology, Medical Faculty of the University of Hamburg
2002 – 2006
Doctorate at Erasmus University, Thesis “Normal and malignant germ cell development”, Erasmus University Rotterdam, Netherlands
Since 1999
Clinical research in geriatric oncology, focusing on geriatric assessment and identification of clinical and biological parameters for assessing the ability of elderly patients to undergo therapy
1996 – 1999
Doctoral thesis (Dr. med.), topic “Molecular mechanisms of growth regulation of tumor cells by the integrin alpha5 beta1”, University Hospital Benjamin Franklin, Berlin, Grade: “magna cum laude”
Memberships
SAKK Swiss Group for Clinical Cancer Research
ESMO European Society for Medical Oncology
DGHO German Society for Hematology and Oncology
FMH Swiss Medical Association
Medical Association of the City of St. Gallen
Medical Society of the Canton of St. Gallen
Member and from 2005 – 2018 Secretary of the Interdisciplinary Working Group on Testicular Tumors (German Testicular Cancer Study Group, GTCSG)
Member and from 2000 – 2018 Secretary of the interdisciplinary working group “Geriatric Oncology” of the DGHO, DGG (German Society for Geriatrics) and AIO (Working Group for Internal Oncology)
Review and editorial activities for numerous scientific journals, including “Annals of Oncology”, “Onkologie”, “International Journal of Andrology”, “BMC Cancer”, “International Journal of Cancer”, “Nature Reviews Urology”, Frontiers in Oncology (Editor Special Issue), Marine Drugs (Associate Editor), Oncology Research and Treatment (Editorial Board).
Reviewer for national and international professional societies and foundations, including the German Society for Hematology and Oncology, International Society of Geriatric Oncology, German Cancer Aid, Wilhelm Sander Foundation, UK Cancer Research Swiss Cancer League and Fundação para a Ciência e a Tecnologia (Portuguese Research Foundation).
Since 2008 Author, since 2013 Author and Editor and since 2018 Main editor of “Pocketbook Hematology and Oncology – Interdisciplinary Recommendations for Therapy”, the most frequently used reference book in oncology/hematology in German-speaking countries (www.onkologie2022.de)
Publications
Honecker, Claßen, Preiß, Dornoff: Pocketbook Hematology and Oncology, Zuckschwerdt-Verlag, Munich 2022/23
Friedemann U. Honecker: Molecular mechanisms of growth regulation of tumor cells by the integrin a5b1, Verlag Buch und Mensch, Berlin 1999
Bokemeyer C, Kollmannsberger C, Hartmann JT, Honecker F, Mayer F, Kanz L: Chemotherapy of urothelial carcinoma of the bladder – update 2001, in „Aktuelle Onkologie“, Zuckschwerdt-Verlag, Munich 2001
Hartmann JT, Kuczyk M, Mayer F, Honecker F, Bokemeyer C: Chemotherapy of metastatic germ cell tumors of the testis, in „Pharmakotherapie urologischer Tumoren“, Springer Verlag Heidelberg 2001
- Wolter Oosterhuis, Friedemann Honecker, Frank Mayer, Carsten Bokemeyer, L.H.J. Looijenga: Pathobiological basis of treatment strategies in Germ Cell Tumors, in “Urological Cancers”, edited by Jonathan Waxman, Springer-Verlag London Limited, 2005
- Honecker, G. Kolb, C. Bokemeyer: Chapter 7.5.4 Cytostatic therapy, growth factors, supportive therapy, in „Kompendium Altersmedizin, Geriatrie – Gerontologie – Gerontotechnik“, edited by H.W. Heiß, ecomed verlagsgesellschaft, 2005
- Honecker, C. Bokemeyer, C.H. Köhne: Chapter 7.5.12 Colorectal carcinoma, in „Kompendium Altersmedizin, Geriatrie – Gerontologie – Gerontotechnik“, edited by H.W. Heiß, ecomed verlagsgesellschaft, 2005
Friedemann Honecker: Normal and Malignant Germ Cell Development. Thesis Erasmus-University 2006
Show more
Ina Thoem, Friedemann Honecker: Bronchial Carcinoma, book chapter in “15 Years of Neutropenia Prophylaxis in Germany”, Springer 2007 Bokemeyer C, Honecker F, Schmieder A: Book chapter on soft tissue sarcomas in “Pocketbook of Oncology: Interdisciplinary Recommendations for Therapy 2008/2009”, pp. 224 – 229, edited by W. Preiß, W. Zuckschwerdt-Verlag, Munich 2008 Bokemeyer C, Honecker F: Book chapter on germ cell tumors in “Pocketbook of Oncology: Interdisciplinary Recommendations for Therapy 2008/2009”, pp. 116 – 121, edited by W. Preiß, W. Zuckschwerdt-Verlag, Munich 2008 Bokemeyer C, Honecker F, Schmieder A: Book chapter on soft tissue sarcomas in “Pocketbook of Oncology: Interdisciplinary Recommendations for Therapy 2010/2011”, pp. 161 – 166, edited by W. Preiß, W. Zuckschwerdt-Verlag, Munich 2010 Honecker F, Bokemeyer C: Book chapter on germ cell tumors in “Pocketbook of Oncology: Interdisciplinary Recommendations for Therapy 2010/2011”, pp. 45 – 50, edited by W. Preiß, W. Zuckschwerdt-Verlag, Munich 2010 Maroni PD, Honecker F, Foster RS: Book chapter 19 Management of late relapse in “Cancer of the Testis”, pp. 263-271, edited by Laguna P, Albers P, Richie JP and Bokemeyer C, Springer-Verlag, London 2011, ISDN 978-1-84800-369-9 Honecker F, Bokemeyer C: Book chapter on testicular tumors in “Rational Diagnostics and Therapy in Internal Medicine”, guideline-based recommendations for practice. ISBN 978-3-437-22849-0 10/2012, edited by N. Jung, W.-J. Mayet, P. R. Mertens, J. Meyer, O.-A. Müller, M. Pfeifer, P. Schellinger, N. Weiss, C.-M. Wendtner, Elsevier, Urban & Fischer, Munich 2013 Honecker F, Bokemeyer C: Book chapter on prostate carcinoma in “Rational Diagnostics and Therapy in Internal Medicine”, guideline-based recommendations for practice. ISBN 978-3-437-22849-0 10/2012, edited by N. Jung, W.-J. Mayet, P. R. Mertens, J. Meyer, O.-A. Müller, M. Pfeifer, P. Schellinger, N. Weiss, C.-M. Wendtner, Elsevier, Urban & Fischer, Munich 2013 Bokemeyer C, Honecker F, Schmieder A: Book chapter on soft tissue sarcomas in “Pocketbook of Oncology: Interdisciplinary Recommendations for Therapy 2012/2013”, pp. 247 – 252, edited by W. Preiß, W. Zuckschwerdt-Verlag, Munich 2012 Honecker F, Bokemeyer C: Book chapter on germ cell tumors in “Pocketbook of Oncology: Interdisciplinary Recommendations for Therapy 2012/2013”, pp. 115 – 121, edited by W. Preiß, W. Zuckschwerdt-Verlag, Munich 2012 Honecker F, Bokemeyer C: Book chapter on gastrointestinal stromal tumors in “Pocketbook of Oncology: Interdisciplinary Recommendations for Therapy 2012/2013”, pp. 103 – 105, edited by W. Preiß, W. Zuckschwerdt-Verlag, Munich 2012 Frenzel T, Honecker F, Krüll A, Petersen C, Yekebas EF: Tumor Detection. 325 pages. ISBN 9783131539618. Thieme Verlag Stuttgart, 2012. (F. Honecker: Co-author of numerous chapters and co-editor) Honecker, F.: Chapter 7.5.4.1 Cytostatic Therapy, Growth Factors and Supportive Measures; Case study: Liver metastasis of a rectal carcinoma, in “Current Geriatric Medicine, Interdisciplinary Geriatric Care”, ISBN 978-3-609-10370-9, edited by H.W. Heiß, ecomed Medizin, 2013 Preiß J, Dornoff W, Schmieder A, Honecker F, Claßen J: Pocketbook of Oncology. Interdisciplinary Recommendations for Therapy 2014/15, ISBN 978-3-86371-108-5. W. Zuckschwerdt-Verlag Munich 2014 (F. Honecker co-editor and (co-)author of 3 chapters) Honecker F, Bokemeyer C, Schmieder A: Book chapter on soft tissue sarcomas in “Pocketbook of Oncology: Interdisciplinary Recommendations for Therapy 2014/2015”, pp. 244-249, edited by W. Preiß, W. Zuckschwerdt-Verlag, Munich 2014 Honecker F, Bokemeyer C: Book chapter on germ cell tumors in “Pocketbook of Oncology: Interdisciplinary Recommendations for Therapy 2014/2015”, pp. 110-116, edited by W. Preiß, W. Zuckschwerdt-Verlag, Munich 2014 Honecker F, Bokemeyer C: Book chapter on gastrointestinal stromal tumors in “Pocketbook of Oncology: Interdisciplinary Recommendations for Therapy 2014/2015”, pp. 99-101, edited by W. Preiß, W. Zuckschwerdt-Verlag, Munich 2014 Preiß J, Honecker F: Book chapter on assessment of therapy success in “Pocketbook of Oncology: Interdisciplinary Recommendations for Therapy 2014/2015”, pp.381-382, edited by W. Preiß, W. Zuckschwerdt-Verlag, Munich 2014 Preiß J, Honecker F: Book chapter on medications in “Pocketbook of Oncology: Interdisciplinary Recommendations for Therapy 2014/2015”, pp.288-354, edited by W. Preiß, W. Zuckschwerdt-Verlag, Munich 2014 Honecker F, Bokemeyer C: Book chapter B 15.1 on testicular tumors in “Rational Diagnostics and Therapy in Internal Medicine”, guideline-based recommendations for practice. pp. 1-7, ISBN 978-3-437-22849-0 10/2012, edited by N. Jung, W.-J. Mayet, P. R. Mertens, J. Meyer, O.-A. Müller, M. Pfeifer, P. Schellinger, N. Weiss, C.-M. Wendtner, Elsevier, Urban & Fischer, Munich 2013 Dyshlovoy SA, Honecker F (Ed.): Marine Compounds and Cancer. ISBN 978-3-03842-132-0, 1st Edition MDPI Basel 2015 Preiß J, Honecker F, Claßen J, Dornoff W: Pocketbook of Oncology. Interdisciplinary Recommendations for Therapy 2016/17, ISBN 978-3-86371-201-3. W. Zuckschwerdt-Verlag Munich 2016 (F. Honecker co-editor and (co-)author of 13 chapters) Honecker F, Claßen J, Preiß J, Dornoff W: Pocketbook of Oncology. Interdisciplinary Recommendations for Therapy 2018/19, ISBN 978-3-86371-261-7. W. Zuckschwerdt-Verlag Munich 2018 (F. Honecker lead editor and (co-)author of 22 chapters) Dyshlovoy SA, Honecker F (Eds.): Marine Compounds and Cancer: 2017 Updates. ISBN 978-3-03842-765-0, 1st Edition MDPI Basel 2018 Dartsch D, Honecker F: Cancer is defeated, but leaves traces. In Dartsch D (Eds.): The cancer patient in the pharmacy. Practical advice. ISBN 978-3-7692-7466-0 Deutscher Apotheker Verlag 2020 Honecker F, Dartsch D: Bone complications. In Dartsch D (Eds.): The cancer patient in the pharmacy. Practical advice. ISBN 978-3-7692-7466-0 Deutscher Apotheker Verlag 2020 Dartsch D, Honecker F: Cancer in old age - every case is unique. In Dartsch D (Eds.): The cancer patient in the pharmacy. Practical advice. ISBN 978-3-7692-7466-0 Deutscher Apotheker Verlag 2020 Honecker F, Claßen J, Preiß J, Dornoff W: Pocket Guide to Oncology. Interdisciplinary Therapy Recommendations 2020/21, ISBN 978-3-86371-303-4. W. Zuckschwerdt-Verlag Munich 2020 (F. Honecker is the main editor and (co-)author of 21 chapters) Honecker F, Claßen J, Preiß J, Dornoff W: Pocket Guide to Hematology and Oncology. Interdisciplinary Therapy Recommendations 202/23, ISBN 978-3-86371-376-8. W. Zuckschwerdt-Verlag Munich 202 (F. Honecker is the main editor and (co-)author of 19 chapters) First author, last author (including equally contributing first and last authorship): Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C: Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anti-Cancer Drugs 2002;13(5):497-503 (IPF 2,0) Honecker F, Kolb G, Bokemeyer C: Treatment of older patients with colorectal carcinoma. Wiener Medizinische Wochenschrift 2002;152(7-8):170-176 Honecker F: Use of hematopoietic growth factors in the chemotherapy of older tumor patients. Euro J Ger 2002;4(1):22-24 Honecker F: Myelosuppression and use of growth factors in older patients. Symposium Medical 2002;13(2):15-16 Honecker F, Köhne CH, Bokemeyer C: Colorectal cancer in the elderly: Is palliative chemotherapy of value? Drugs Aging 2003;20(1):1-11 (IPF 2,0) Honecker F, Bokemeyer C: Chemotherapy in elderly patients with advanced colorectal cancer. Eur J Ger 2003;5 No.S1:40-45 Honecker F, Mayer F, Stoop H, Oosterhuis JW, Koch S, Bokemeyer C, Looijenga LHJ: Xeroderma pigmentosum group A protein and chemotherapy resistance in human germ cell tumors. Lab Invest 2003;83(10):1489-1495 (IPF 4,0) Honecker F, Oosterhuis JW, Mayer F, Hartmann JT, Bokemeyer C, Looijenga LH: New insights into the pathology and molecular biology of human germ cell tumors. World J Urol 2004;22(1):15-24 (IPF 2,0) Honecker F, Stoop H, de Krijger RR, Chris Lau YF, Bokemeyer C, Looijenga LH: Pathobiological implications of the expression of markers of testicular carcinoma in situ by fetal germ cells. J Pathol 2004;203(3):849-857 (IPF 6,0) Honecker F, Kersemaekers AMF, Molier M, van Weeren PC, Stoop H, de Krijger RR, Wolffenbuttel KP, Oosterhuis JW, Bokemeyer C, Looijenga LHJ: Involvement of E-cadherin and beta-catenin in germ cell tumours and in normal male fetal germ cell development. J Pathol 2004;204:167-174 (IPF 6,0) Honecker F, Wedding U, Bokemeyer C: Chemotherapy in elderly patients with advanced lung cancer. Part I: General aspects and treatment of small cell lung cancer (SCLC). Onkologie 2004;27(5):500-505 (IPF 1,2) Honecker F, Wedding U, Bokemeyer C: Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC). Onkologie 2004;27(6):583-588 (IPF 1,2) Stoop H, Honecker F, Cools M, de Krijger RR, Bokemeyer C, Looijenga LHJ: Differentiation and development of human female germ cells during prenatal gonadogenesis: an immunohistochemical study. Hum Reprod 2005;20(6):1466-1476 (IPF 3,6) Kersemaekers AMF, Honecker F, Cools M, Stoop H, Molier M, Wolffenbuttel KP, Bokemeyer C, Li Y, Lau Y-FC, Oosterhuis JW, Looijenga LHJ: Identification of germ cells at risk for neoplastic transformation in gondadoblastomas An immunohistochemical study for OCT 3/4 and TSPY. Hum Pathol 2005;36:512-521 (IPF 2,5) Honecker F, Andres M, Bokemeyer C, Jakob A: The systemic treatment of older tumor patients. Geriatrie Journal 2005;6:21-24 Honecker F, Andres M, Souchon R, Bokemeyer C: Too old for chemotherapy? Klinikarzt 2005;34(11):313-317 Honecker F, Stoop H, Mayer F, Bokemeyer C, Castrillon DH, Lau Y-FC, Looijenga LHJ, Oosterhuis JW: Germ cell lineage differentiation in nonseminomatous germ cell tumours. J Pathol 2006;208:395-400 (IPF 5,7) Honecker F, Andres M, Souchon R, Bokemeyer C: Too old for chemotherapy? Emergency & General Practice Medicine 2006;32(1):23-27 Honecker FU, Brummendorf TH, Klein O, Bokemeyer C: Safe use of oxaliplatin in a patient with metastatic breast cancer and combined renal and hepatic failure. Onkologie 2006;29(6):273-275 (IPF 1,7) Honecker F, Bokemeyer C: A registry for elderly cancer patients – Data collection of the IN-GHO initiativeâ Onkologie heute 2006;6:20-21 Honecker F: Normal and malignant germ cell development. CritRev Oncog 2006;12(3-4):297-299 Honecker F, Bokemeyer C: Geriatric oncology: What special considerations need to be taken into account? internistische praxis 2007;47(2):351-357; identical wording also appeared in tägliche praxis 2007;48:513-519, identical wording also appeared in gynäkologische praxis 2010 Honecker F, Thoem I, Branscheid T, Wendt TG: Bronchial carcinoma treatment of patients over 70 years – risk-adjusted approach. Onkologe 2007;13:823-830 Honecker F, Kolb G, Bokemeyer C: Supportive therapy in geriatric oncology. Forum 2008;23:3537 Stoop H, Honecker F, van de Geijn GJM, Gillis AJM, Cools MC, de Boer M, Bokemeyer C, Wolffenbuttel K, Drop SLS, de Krijger RR, Shipley J, Oosterhuis JW, Looijenga LHJ: Stem Cell Factor as novel diagnostic marker in early malignant germ cells. J Pathol 2008;216(1):43-54 (IPF 5,1) Honecker F, Oechsle K, Bub J, Hartmann F, Mayer F, Bokemeyer C: Refractory germ cell tumors: Biology and treatment concepts. Onkologe 2008; 14: 575-580 Glaesener S, Honecker F, Veltman IM, Gillis AJM, Rohlfing T, Streichert T, Otto B, Brummendorf TH, Looijenga LHJ, Bokemeyer C, Balabanov S: Comparative proteome, transcriptome, and genome analysis of a gonadal and an extragonadal germ cell tumor cell line. J Proteome Res 2008;7(9):3890-3899 (IPF 5,7) Honecker F, Wermann H, Mayer F, Gillis AJM, Stoop H, van Gurp RJ, Oechsle K, Steyerberg E, Hartmann JT, Dinjens WMN, Oosterhuis JW, Bokemeyer C, Looijenga LHJ: Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment resistant germ cell tumors. J Clin Oncol 2009;27(13):2129-2136 (IPF 17,8) Honecker F, Bokemeyer C: Registries and Clinical trials in Geriatric Oncology in Germany. Onkologie 2009;32 suppl 3:14-18 (IPF 1,2) Honecker F, Kolb G: Geriatric oncology: The future has begun. best practice onkologie 2009;4 (6):46-54 Oechsle K, Bokemeyer C, Honecker F: Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors. J Cancer Res Clin Oncol 2010;136:165-167 (IPF 2,2) Honecker F, Bokemeyer C: Patients with advanced non-seminomatous germ cell tumours: the art of the start. Ann Oncol 2010;21(8):1569-1571 (IPF 5,0) Honecker F, Souchon R, Krege S, Bokemeyer C: Therapy of testicular tumors. best practice onkologie 2010;5:4-13 Honecker F, Souchon R, Krege S, Bokemeyer C: Multimodal therapy concepts of germ cell tumors – A multidisciplinary approach to the treatment of germ cell tumors. Der Internist 2010;51:1382-1387 (IPF 0,3) Mayer F, Wermann H, Albers P, Stoop H, Gillis AJM, Hartmann JT, Bokemeyer C, Oosterhuis JW, Looijenga LHJ, Honecker F: Histopathological and molecular features of late relapses in nonseminomas. BJU Int 2011;107(6):936-943 (IPF 2,8) Oechsle K, Honecker F, Cheng T, Mayer F, Czaykowski P, Winquist E, Wood L, Fenner M, Glaesener S, Hartmann JT, Chi K, Bokemeyer C, Kollmannsberger C: Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann Oncol 2011;22(12):2654-2660 (IPF 5,6) Koychev D, Oechsle K, Bokemeyer C, Honecker F: Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update. Int J Androl 2011;34(4 Pt 2):e266-73 (IPF 3,6) Oechsle K, Bokemeyer C, Kollmannsberger C, Mayer F, Berger LA, Oing C, Honecker F: Bone metastases in germ cell tumor patients. J Cancer Res Clin Oncol 2012;138(6):947-952 (IPF 2,5) Dyshlovoy SA, Naeth I, Venz S, Preukschas M, Sievert H, Jacobsen C, Shubina LK, Gesell Salazar M, Scharf C, Walther R, Krepstakies M, Priyadarshini P, Hauber J, Fedorov SN, Bokemeyer C, Stonik VA, Balabanov S, Honecker F: Proteomic profiling of germ cell cancer cells treated with aaptamine, a marine alkaloid with antiproliferative activity. J Proteome Res 2012;11(4):2316-2330 (IPF 5,4) Dyshlovoy SA, Fedorov SN, Kalinovsky AI, Shubina LK, Bokemeyer C, Stonik VA, Honecker F: Mycalamide A shows cytotoxic properties and prevents EGF-induced neoplastic transformation through inhibition of nuclear factors. Marine Drugs 2012;10(6):1212-1224 (IPF 3,9) Janjetovic S, Bokemeyer C, Fiedler W, Frenzel T, Calaminus G, Honecker F: Late Recurrence of a Pineal Germinoma 14 Years after Radiation and Chemotherapy: A Case Report and Review of the Literature. Onkologie 2013;36(6):371-373 (IPF 1,0) Honecker F, Koychev D, Luhmann AD, Langer F, Dieckmann KP, Bokemeyer C, Oechsle K: Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy. Onkologie 2013;36(11)663-668 (IPF 1,0) Honecker F, Rohlfing T, Harder S, Braig M, Gillis AJM, Glaesener S, Barett C, Bokemeyer C, Buck F, Brümmendorf TH, Looijenga LHJ, Balabanov S: Proteome analysis of the effects of all-trans retinoic acid on human germ cell tumor cell lines. J Prot 2014; 96:300-313 (IPF 4,0) Dyshlovoy SA, Venz S, Shubina LK, Fedorov S, Walther R, Jacobsen C, Stonik VA, Bokemeyer C, Balabanov S, Honecker F: Activity of aaptamine and two derivatives, demethyloxyaaptamine and isoaaptamine, in cisplatin-resistant germ cell cancer. J Prot 2014; 96:223-239 (IPF 4,0) Honecker F: Bone metastases and bone-targeted therapy in prostate cancer. Leading opinions Hämatologie & Onkologie 2013;6:106-108 Honecker F: Drug therapy for metastatic renal cell carcinoma. Leading opinions Innere Medizin 2013;5:66-72 Oing C, Wagner R, Bokemeyer C, Honecker F: Lymphonodal, pulmonary, and pleural gliomatosis in a 42-year old male with non-seminomatous testicular germ cell cancer. Histopathology 2014;65:142-42 (IPF 3,3) Nastaly P, Ruf CG, Becker P, Bednarz-Knoll N, Stoupiec M, Kavsur R, Isbarn H, Matthies C, Wagner W, Höppner D, Fisch M, Bokemeyer C, Ahyai S, Honecker F, Riethdorf S, Pantel K: Circulating tumor cells in patients with testicular germ cell tumors. Clin Cancer Res 2014;20:3830-41 (IPF 8,1) Dyshlovoy SA, Fedorov SN, Shubina LK, Kuzmich AS, Bokemeyer C, Keller-von Amsberg G, Honecker F: Aaptamines from the marine sponge Aaptos sp. Display anticancer activities in human cancer cell lines and modulate AP-1-, NF-κB- and p53-dependent transcriptional activity in mouse JB6 C141 cells. Biomed Res Int vol. 2014 (IPF 2,7) Jacobsen C, Honecker F: Cisplatin resistance in germ cell tumours: Models and mechanisms. Andrology 2015;3(1):111-121 (IPF unknown) Dyshlovoy SA, Hauschild J, Amann K, Tabakmakher K, Venz S, Walther R, Guzii AG, Makarieva TN, Shubina LK, Fedorov SN, Stonik VA, Bokemeyer C, Balabanov S, Honecker F, von Amsberg G: Marine alkaloid Monanchocidin a overcomes drug resistance by induction of autophagy and lysosomal membrane permeabilization. Oncotarget 2015;6(19):17328-173241 (IPF 6,4) Steinemann G, Jacobsen C, Gerwing M, Hauschild J, von Amsberg G, Höpfner M, Nitzsche B, Honecker F: Activity of nintedanib in germ cell tumors. Anticancer Drugs 2016;27(2):89-98 (IPF 1,8) Dyshlovoy SA, Honecker F: Marine Compounds and Cancer: Where Do We Stand? Marine Drugs 2015;13(9):5657-5665 (IPF 2,8) Dyshlovoy SA, Menchinskaya ES, Venz S, Rast S, Amann K, Hauschild J, Otte K, Kalinin VI, Silchenko AS, Avilov SA, Alsdorf W, Madanchi R, Bokemeyer C, Schumacher U, Walther R, Aminin DL, Fedorov SN, Shubina LK, Stonik VA, Balabanov S, Honecker F, von Amsberg G: The marine triterpene glycoside frondoside A exhibits activity in vitro and in vivo in prostate cancer. Int J Cancer 2016;138(19) :2450-2465 (IPF 5,1) Gerwing M, Jacobsen C, Dyshlovoy S, Hauschild J, Rohlfing T, Oing C, Venz S, Oldenburg J, Oechsle K, Bokemeyer C, von Amsberg G, Honecker F: Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells. J Cancer Res Clin Oncol 2016;142(9):1979-1994 (IPF: 3,5) Honecker F, Harbeck N, Schnabel C, Wedding U, Waldenmaier D, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba B, Dorn J, Warm M, Al-Batran SE, de Wit M; PELICAN investigators: Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial. J Geriatr Oncol 2017;S1879-4068(17):30195-9 (IPF: 2,8) Honecker F, Wedding U, Kallischnigg G, Schroeder A, Klier J, Frangenheim T, Weißbach L: Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study. J Cancer Res Clin Oncol. 2018;144(3):571-577 (IPF: 3,2) Honecker F, Dartsch D: Getting into the bones: Osseous complications in cancer patients. Deutsche Apotheker Zeitung 2018;158(4):336-343 Dyshlovoy SA, Honecker F: Marine Compounds and Cancer: Update 2017. Marine Drugs 2018 (IPF 3,5) Honecker F, Wedding U, Kallischnigg G, Schroeder A, Klier J, Frangenheim T, Weißbach L: Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study. Urologe A. 2018;57(8):909-918 (IPF 0,19) Dyshlovoy SA, Honecker F: Marine Compounds and Autophagy: Beginning of a New Era. Mar Drugs 2018;16(8) (IPF 4,3) Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, Giannatempo P, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A: ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol 2018;29(8):1658-1686 (IPF 13,9) Fenner M, Oing C, Dieing A, Gauler T, Oechsle K, Lorch A, Hentrich M, Kopp HG, Bokemeyer C, Honecker F: Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group. J Cancer Res Clin Oncol 2018 Sep 19. doi: 10.1007/s00432-018-2752-z. [Epub ahead of print] (IPF 3,2) Oing C, Verem I, Mansour WY, Bokemeyer C, Dyshlovoy S, Honecker F: 5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells. Int J Mol Sci 2018 Dec 21;20(1). pii: E21. doi: 10.3390/ijms20010021 (IPF 3,7) Honecker F, Dartsch D: Cancer in old age - every case is unique. Deutsche Apotheker Zeitung 2018;158(39), 64-73 Dartsch D, Honecker F: The cancer is defeated, but leaves traces. Deutsche Apotheker Zeitung 2019;159(9), 46-53 Bremmer F, Bohnenberger H, Küffer S, Oellerich T, Serve H, Urlaub H, Strauss A, Maatoug Y, Behnes CL, Oing C, Radzun HJ, Ströbel P, Balabanov S, Honecker F: Proteomic Comparison of Malignant Human Germ Cell Tumor Cell Lines. Dis Markers 2019 Sep 3;2019:8298524 (IPF 2,9) Dyshlovoy SA, Honecker F: Marine Compounds and Cancer: The First Two Decades of XXI Century. Mar Drugs 2019 Dec 26;18(1) (IPF 4,3) Dyshlovoy SA, Honecker F: Marine Drugs Acting as Autophagy Modulators. Mar Drugs 2020 Jan 14;18(1) (IPF 3,7) Hennigs JK, Minner S, Tennstedt P, Löser R, Huland H, Klose H, Graefen M, Schlomm T, Sauter G, Bokemeyer C, Honecker F: Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer. Sci Rep 2020 Feb 24;10(1):3250 (IPF 4,0) Dyshlovoy SA, Honecker F: Marine Compounds and Cancer: Updates 2020. Marine Drugs 2020 Dec 15;18(12):643 (IPF 4,8) Honecker F, Huschens S, Angermund R, Kallischnigg G, Freier W, Friedrich C, Hartung G, Lutz A, Otremba B, Pientka L, Späth-Schwalbe E, Kolb G, Bokemeyer C, Wedding U; Initiative Geriatrische Hämatologie und Onkologie (IN-GHO®): Patient assessment and feasibility of treatment in older patients with cancer: results from the IN-GHO ® Registry. J Cancer Res Clin Oncol 2021 Nov;147(11):3183-3194 (IPF 4,5) Co-author: Bokemeyer C, Honecker F, Wedding U, Späth-Schwalbe E, Lipp HP, Kolb G; DGHO/DGG study group „Geriatrische Onkologie“ (Geriatric Oncology): Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy. Onkologie 2002;25(1):32-39 (IPF 1,2) Mayer F, Honecker F, Looijenga LHJ, Bokemeyer C: Towards understanding of the biological basis of the response to cisplatin-based chemotherapy in germ cell tumors. Ann Oncol, 2003;14(6):825-832 (IPF 4,5) Looijenga LHJ, Stoop H, de Leeuw HPJC, de Gouveia Brazao CA, Gillis AJM, van Roozendaal KEP, van Zoelen EJJ, Weber RFA, Wolffenbuttel KP, van Dekken H, Honecker F, Bokemeyer C, Perlman EJ, Schneider DT, Kononen J, Sauter G, Oosterhuis JW: POU5F1 (OCT3/4) identifies cell with pluripotent potential in human germ cell tumors. Cancer Res, 2003;63(9):2244-2250 (IPF 7,5) Bokemeyer C, Honecker F: Chemotherapy for geriatric oncology patients: a challenge for the future. Medizin im Dialog 2003;2:1-6 Hartmann JT, Oechsle K, Quietzsch D, Wein A, Hofheinz RD, Honecker F, Nehls O, Kohne CH, Kafer G, Kanz L, Bokemeyer C: Protracted infusional 5-fluorouracil plus high dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. Br J Cancer 2003;89(11):2051-2056 (IPF 4,5) Koch S, Mayer F, Honecker F, Schittenhelm M, Bokemeyer C: Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J Cancer 2003;89(11):2133-2139 (IPF 4,5) Bokemeyer C, Honecker F: Chemotherapy for advanced colorectal carcinoma: Treatment options for older patients. Onkologie 2003;26(suppl 7):48-53 (IPF 1,2) Cools M, Honecker F, Stoop H, Veltman J, de Krijger RR, Steyerberg E, Wolffenbuttel KP, Bokemeyer C, Lau Y-FC, Drop SLS, Looijenga LHJ: Maturation delay of germ cells in fetuses with trisomy 21 results in increased risk for the development of testicular germ cell tumors. Hum Pathol 2006;37:101-111 (IPF 2,8) Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C: A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006;17(6):1007-1013 (IPF 5,2) Mueller S, Schittenhelm M, Honecker F, Malenke E, Lauber K, Wesselborg S, Hartmann JT, Bokemeyer C, Mayer F: Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. Int J Oncol 2006;29(2):471-479 (IPF 2,5) Krege S, Wittekind C, Souchon R, Honecker F, Bokemeyer C, Albers P, Gschwend J, Rubben H: Testicular cancer: Yesterday – Today – Tomorrow. Urologe 2006;45 suppl 4:169-175 (IPF 0,4) Kollmannsberger C, Honecker F, Bokemeyer C: Treatment of germ cell tumors – update 2006. Ann Oncol 2006;17 suppl 10:31-35 (IPF 5,2) Wedding U, Honecker F, Pientka L, Bokemeyer C, Hoffken K: Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 2007;14(1):44-56 Martineau AR, Honecker F, Wilkinson RJ, Griffiths CJ: Vitamin D in the treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol 2007;103(3-5):793-798 (IPF 2,8) Oechsle K, Honecker F, Kollmannsberger C, Rick O, Grunwald V, Mayer F, Hartmann JT, Bokemeyer C: An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors. Anti-Cancer Drugs 2007;18(3):273-276 (IPF 2,3) Oechsle K, Honecker F, Beyer J, Bokemeyer C: Significance of high-dose chemotherapy in malignant germ cell tumors. Onkologe 2007;13:434-440 Albers P, Honecker F, Ruschoff J, Sauter G, Muller SC, Buttner R, Bokemeyer C: Molecular biological investigations of late relapse in testicular tumors. Urologe 2007; 46(9)1185-1186 (IPF 0,4) Oosterhuis JW, Stoop H, Honecker F, Looijenga LHJ: Why human extragonadal germ cell tumours occur in the midline of the body: old concepts, new perspectives. Int J Androl 2007;30:256-264 (IPF 3,0) Wedding U, Honecker F, Pientka L, Höffken K: Clinical trials and patient registries for older patients with cancer. Onkologe 2007;13:783-791 (IPF 1,3) Bokemeyer C, Oechsle K, Honecker F, Mayer F, Hartmann JT, Waller CF, Böhlke I, Kollmannsberger C: Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 2008;19:448-453 (IPF 4,9) Kollmannsberger C, Oechsle K, Honecker F, Mayer F, Bokemeyer C: Treatment of patients with metastatic germ cell tumors. Onkologe 2008;14:593-601 Oechsle K, Kollmannsberger C, Honecker F, Boehlke I, Bokemeyer C: Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy. Eur J Cancer 2008;44(12):1663-1669 (IPF 4,5) Kollmannsberger C, Honecker F, Bokemeyer C: Pharmacotherapy of relapsed metastatic testicular cancer. Expert Opin Pharmacother 2008;9(13):2259-2272 (IPF 2,0) Schittenhelm MM, Kollmannsberger C, Oechsle K, Harlow A, Morich J, Honecker F, Kurek R, Störkel S, Kanz L, Corless CL, Wong KK, Bokemeyer C, Heinrich MC: Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol Cancer Ther 2009;8(3):481-489 (IPF 4,9) Oechsle K, Lorch A, Honecker F, Kollmannsberger C, Hartmann JT, Boehlke I, Beyer J, Bokemeyer C. Patterns of relapse after Chemotherapy in patients with high risk nonseminomatous germ cell tumor. Oncology 2010;78(1):47-53 (IPF 2,1) Wermann H, Stoop H, Gillis AJM, Honecker F, van Gurp RJ, Ammerpohl O, Richter J, Oosterhuis JW, Bokemeyer C, Looijenga LHJ: Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance. J Pathol 2010;221(4):433-442 (IPF 6,5) Port M, Glaesener S, Ruf C, Rieke A, Bokemeyer C, Meineke V, Honecker F, Abend M: Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 2011;10(1):52 (IPF 4,1) Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C, Brummendorf TH, Klose H. Multi tyrosine kinase inhibitor dasatinib as a novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 2011;11(1):30 (unofficial IPF 1,9) Oechsle K, Kollmannsberger C, Honecker F, Mayer F, Waller CF, Hartmann JT, Boehlke I, Bokemeyer C; German Testicular Cancer Study Group: Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol 2011;60(4):850-5 (IPF 8,8) Fenske AE, Glaesener S, Bokemeyer C, Thomale J, Dahm-Daphi J, Honecker F, Dartsch DC: Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repair. Cancer Lett 2012;324(2):171-178 (IPF 4,2) Nitzsche B, Gloesenkamp C, Schrader M, Hoffmann B, Zengerling F, Balabanov S, Honecker F, Höpfner M: Antitumor activity of two novel compounds in cisplatin resistant testicular germ cell cancer. Br J Cancer 2012;107(11):1853-63 (IPF 5,0) Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, Müller SC, Albers P, Gschwend J, Wirth M, Steiner U, Miller K, Heinrich E, Bolenz C, Volkmer B, de Geeter P, Honecker F, Bokemeyer C, Keck B, Goebell P, Otremba B, Ecstein-Fraisse E, Pfister D: Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the german compassionate use program. Eur Urol 2013;63(6):977-982 (IPF 8,5) Beyer J, Albers P, Altena R, Aaparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Claßen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germa-Lluch JR, Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LHJ, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C: Maintaining Success, Reducing Treatment Burden, Focusing on Survivorship: Highlights from the Third European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer. Ann Oncol 2013;24(4):878-888 (IPF 6,4) Nettersheim D, Heukamp LC, Fronhoffs F, Grewe MJ, Haas N, Waha A, Honecker F, Waha A, Kristiansen G, Schorle H: Analysis of TET Expression/Activity and 5mC Oxidation during Normal and Malignant Germ Cell Development. PLoS One 2013 Dec 26 (IPF 3,7) Pelageev DN, Dyshlovoy SD, Pokhilo ND, Denisenko VA, Borisova KL, Keller-von Amsberg G, Bokemeyer C, Fedorov SN, Honecker F, Anufriev VP: Quinone-carbohydrate nonglucoside conjugates as a new type of cytotoxic agents: Synthesis and determination of in vitro activity. Eur J Med Chem 2014;77:139-44 (IPF 3,5) Berger LA, Bokemeyer C, Lorch A, Hentrich M, Kopp HG, Gauler TC, Beyer J, de Wit M, Mayer F, Boehlke I, Oing C, Honecker F, Oechsle K: First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). J Cancer Res Clin Oncol 2014; April 4 140(7):1211-1220 (IPF 2,9) Oldenburg J, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M, Gilligan T, De Giorgi U, De Santis M, de Wit R, Fosså SD, Germà-Lluch JR, Gillessen S, Haugnes HS, Honecker F, Horwich A, Lorch A, Ondruscaron D, Rosti G, Stephenson A, Tandstad T: Personalizing, not patronizing: The case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol Nov 2014 (Epub ahead of print) (IPF 5,8) Oing C, Lorch A, Bokemeyer C, Honecker F, Beyer J, Berger LA, Oechsle K: First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database. J Cancer Res Clin Oncol 2015;141(5):923-931 (IPF 2,9) Niegisch G, Retz M, Thalgott M, Balabanov S, Honecker F, Ohlmann CH, Stöckle M, Bögemann M, Vom Dorp F, Gschwend J, Hartmann A, Ohmann C, Albers P: Second-line treatment of advanced urothelial cancer with paclitaxel and everolimus in a German phase II trial (AUO Trial AB 35/09). Oncology 2015;89(2):70-78 (IPF 2,6) Jacobsen C, Oechsle K, Hauschild J, Steinemann G, Spath B, Bokemeyer C, Ruf W, Honecker F, Langer F: Regulation of tissue factor in NT2 germ cell tumor cells by cisplatin chemotherapy. Throm Res 2015;136(3):673-681 (IPF 2,4) Goede V, Bahlo J, Chataline V, Eichhorst B, Dürig J, Stilgenbauer S, Kolb G, Honecker F, Wedding U, Hallek M: Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. Leukemia Lymphoma Oct 2015 (Epup ahead of print) (IPF 2,9) Fankhauser CD, Honecker F, Beyer J, Bode PK: Emerging Therapeutic Targets for Male Germ Cell Tumors. Curr Oncol Rep 2015;17(12):54 (IPF 2,9) Bremmer F, Schallenberg S, Jarry H, Küffer S, Kaulfuss S, Burfeind P, Strauß A, Thelen P, Radzun HJ, Ströbel P, Honecker F, Behnes CL: Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours. Oncotarget 2015;6(32): 33426-33437 (IPF 6,4) Dyshlovoy SA, Venz S, Hauschild J, Tabakmakher KM, Otte K, Madanchi R, Walther R, Guzii AG, Makarieva TN, Shubina LK, Fedorov SN, Stonik VA, Bokemeyer C, Balabanov S, Honecker F, V Amsberg G: Anti-migratory activity of marine alkaloid monanchocidin A – proteomics-based discovery and confirmation. Proteomics 2016;16(10):1590-603 (IPF 4,1) Dyshlovoy SA, Tabakmakher KM, Hauschild J, Shchekaleva RK, Otte K, Guzii AG, Makarieva TN, Kudryashova EK, Fedorov SN, Shubina LK, Bokemeyer C, Honecker F, Stonik VA, von Amsberg G: Guanidine Alkaloids from the Marine Sponge Monanchora pulchra Show Cytotoxic Properties and Prevent EGF-Induced Neoplastic Transformation in Vitro. Mar Drugs 2016;14(7) (IPF 3,3) Nettersheim D, Jostes S, Fabry M, Honecker F, Schumacher V, Kirfel J, Kristiansen G, Schorle H: A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment. Oncotarget 2016;7(46):74931-74946 (IPF 3,4) Dyshlovoy SA, Otte K, Alsdorf WH, Hauschild J, Lange T, Venz S, Bauer CK, Bähring R, Amann K, Mandanchi R, Schumacher U, Schröder-Schwarz J, Makarieva TN, Guzii AG, Tabakmakher KM, Fedorov SN, Shubina LK, Kasheverov IE, Ehmke H, Steuber T, Stonik VA, Bokemeyer C, Honecker F, von Amsberg G: Marine compound rhizochalinin shows high in vitro and in vivo efficacy in castration resistant prostate cancer. Oncotarget 2016; 7(43):69703-69717 (IPF 3,4) Fedorov SN, Stonik VA, Honecker F, Dyshlovoy S: Structure-activity relationship studies of new marine anticancer agents and their synthetic analogues. Curr Med Chem 2016 (IPF 3,5) Dyshlovoy SA, Madanchi R, Hauschild J, Otte K, Alsdorf WH, Schumacher U, Kalinin VI, Silchenko AS, Avilov SA, Honecker F, Stonik VA, Bokemeyer C, von Amsberg G: The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells. BMC Cancer 2017;17(1):93 (IPF 3,7) Dyshlovoy SA, Otte K, Venz S, Hauschild J, Junker H, Makarieva TN, Balabanov S, Alsdorf WH, Madanchi R, Honecker F, Bokemeyer C, Stonik VA, von Amsberg G: Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalinin. Proteomics June 2017 (IPF 4,1) Jostes S, Nettersheim D, Fellermeyer M, Schneider S, Hafezi F, Honecker F, Schumacher V, Geyer M, Kristiansen G, Schorle H: The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo. J Cell Mol Med 2017; 21(7):1300-1314 (IPF 5,1) Dyshlovoy SA, Rast S, Hauschild J, Otte K, Alsdorf WH, Madanchi R, Kalinin VI, Silchenko AS, Avilov SA, Dierlamm J, Honecker F, Stonik VA, Bokemeyer C, von Amsberg G: Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells. Leuk Lymphoma 2017;58(12):2905-2915 (IPF 2,7) Oing C, Giannatempo P, Honecker F, Oechsle K, Bokemeyer C, Beyer J: Palliative treatment of germ cell cancer. Cancer Treat Rev 2018 Dec;71:102-107 (IPF 8,6) Pazan F, Weiss C, Wehling M; FORTA: The FORTA (Fit fOR The Aged) List 2018: Third Version of a Validated Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging 2019 May;36(5):481-484 (IPF 2,3) Lobo J, Guimarães-Teixeira C, Barros-Silva D, Miranda-Gonçalves V, Camilo V, Guimarães R, Cantante M, Braga I, Maurício J, Oing C, Honecker F, Nettersheim D, Looijenga LH, Henrique R, Jerónimo C: Efficacy of HDAC inhibitors belinostat and panobinostat against cisplatin-sensitive and cisplatin-resistant testicular germ cell tumors. Cancers 2020 Oct 10;12(10):2903-2922 (IPF 6,4) Nastaly P, Honecker F, Pantel K, Riethdorf S: Detection of circulating tumor cells (CTCs) in patients with testicular germ cell tumors. Methods Mol Biol 2021;2195:245-261 (IPF 10,3) Skowron MA, Oing C, Bremmer F, Ströbel P, Murray MJ, Coleman N, Amatruda JF, Honecker F, Bokemeyer C, Albers P, Nettersheim D: The developmental origin of cancers defines basic principles of cisplatin resistance. Cancer Lett 2021 Oct 28;519:199-210 (IPF 8,7) Miranda-Gonçalves V, Lobo J, Guimarães-Teixeira C, Barros-Silva D, Guimarães R, Cantante M, Braga I, Maurício J, Oing C, Honecker F, Nettersheim D, Looijenga LHJ, Henrique R, Jerónimo C: The component of the m 6 A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors. J Exp Clin Cancer Res 2021 Aug 25;40(1):268 (IPF 9,9) Beyer J, Berthold D, Bode PK, Cathomas R, Fankhauser CD, Fischer S, Gillessen S, Gross T, Hermanns T, Honecker F, Lorch A, Omlin A, Papachristofilou A, Roth B, Rothermundt C, Seiler R, Spahn M, Stenner F, Bührer E: Swiss germ-cell cancer consensus recommendations. Swiss Med Wkly. 2021 Aug 23;151(33-34) (IPF 1,8)